Therapy Analysis - Drug addiction
The future?
The development pipeline for pharmacotherapeutics for drug addiction (Graph 1) shows that there are many companies active in this area, including some traditional big pharma such as Pfizer, Eli Lilly and Merck KGaA, as well as a host of small-to-middle size pharma and biotech enterprises. Indeed, no one company dominates the area and there is still much room for improvement over existing therapies. As has been seen, much of the research is currently focused on improved formulations of existing drugs. With drug use a continuing social and economic problem worldwide, it is hoped that as the mechanisms of addiction are further elucidated, new pharmacological strategies will be developed.
Andrew Benson
Pharmaprojects Analyst
